Major reduction of NKT cells in patients with severe COVID-19 pneumonia

Zingaropoli, Maria Antonella; Perri, Valentina; Pasculli, Patrizia; Dezza, Francesco Cogliati; Nijhawan, Parni; Savelloni, Giulia; Torre, Giuseppe La; D’Agostino, Claudia; Mengoni, Fabio; Lichtner, Miriam; Ciardi, Maria Rosa; Mastroianni, Claudio Maria

doi:10.1016/j.clim.2020.108630

Cited by 45 publications

(60 citation statements)

References 38 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here we identified a dra-matic, early loss of NKT cells in the circulating immune compartment of COVID-19s. Although others confirmed this observation (Zhang et al, 2020a;Zingaropoli et al, 2021), here we found this phenomenon indeed to not be shared across severe RS patients but to be specific to the SARS-CoV-2 immune response. NKT cells are important for the production of an early wave of IL-4 promoting germinal center (GC) formation during viral infection.…”

Section: Discussioncontrasting

confidence: 57%

Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia

et al. 2021

View full text Add to dashboard Cite

Immune profiling of COVID-19 patients has identified numerous alterations in both innate and adaptive immunity. However, whether those changes are specific to SARS-CoV-2 or driven by a general inflammatory response shared across severely ill pneumonia patients remains unknown. Here, we compared the immune profile of severe COVID-19 with non-SARS-CoV-2 pneumonia ICU patients using longitudinal, high-dimensional single-cell spectral cytometry and algorithm-guided analysis. COVID-19 and non-SARS-CoV-2 pneumonia both showed increased emergency myelopoiesis and displayed features of adaptive immune paralysis. However, pathological immune signatures suggestive of T cell exhaustion were exclusive to COVID-19. The integration of single-cell profiling with a predicted binding capacity of SARS-CoV-2-petides to the patients’ HLA profile further linked the COVID-19 immunopathology to impaired virus recognition. Towards clinical translation, circulating NKT cell frequency was identified as a predictive biomarker for patient outcome. Our comparative immune map serves to delineate treatment strategies to interfere with the immunopathologic cascade exclusive to severe COVID-19.

show abstract

Section: Discussioncontrasting

confidence: 57%

Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These findings are particularly relevant in the context of severe COVID-19 with ARDS, indicating NKT cells could also play a beneficial role in the context of SARS-CoV-2 infection. Actually, it has been reported that the percentage of NKT-like cells in the peripheral blood is significantly lower in the severe COVID-19 group than in the nonsevere one and is positively correlated with the pressure of arterial oxygen/fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio in patients ( 44 ). In addition, the activation marker CD69 expression on iNKT cells of COVID-19 patients on admission was also found to be positively correlated with the PaO 2 /FiO 2 ratio and is believed to be predictive of clinical course and disease severity in severe COVID-19 ( 45 ).…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment

Liu

Yang

Wang

et al. 2021

mBio

View full text Add to dashboard Cite

show abstract

“…Patients with severe COVID-19 have a lower number of natural killer (NK) cells and a higher level of the C-reactive protein. The early failure of antiviral immunity during SARS-CoV-2 infection is correlated with a significant decrease in total T cells and NK cells [16].…”

Section: Viral Host and Immune Targets In Covid-19mentioning

confidence: 99%

A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19

Costa

Vale

2021

Pharmaceutics

View full text Add to dashboard Cite

The pandemic of the coronavirus disease 2019 (COVID-19) represents an unprecedented challenge to identify effective drugs for prevention and treatment. While the world’s attention is focused on news of COVID-19 vaccine updates, clinical management still requires improvement. Due to the similarity of cancer-induced inflammation, immune dysfunction, and coagulopathy to COVID-19, anticancer drugs, such as Interferon, Pembrolizumab or Bicalutamide, are already being tested in clinical trials for repurposing, alone or in combination. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected, clinicians need effective medical treatments for this infection.

show abstract

Major reduction of NKT cells in patients with severe COVID-19 pneumonia

Cited by 45 publications

References 38 publications

Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia

Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia

Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment

A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19

Contact Info

Product

Resources

About